Marketing in Brief: SmithKline Beecham
This article was originally published in The Rose Sheet
Executive Summary
SmithKline Beecham: Signs agreement with Foster City, Calif.-based Penederm to develop an OTC product using Penederm's TopiCare delivery compounds, Penederm said April 8. The product will be launched in about a year. TopiCare "traps" an active ingredient in the upper layers of skin, Penederm explained, to prevent wash-off and modulate the absorption of the active into the skin. Under the deal, SmithKline holds the exclusive option to market the finished product worldwide, and Penederm will receive milestone payments and royalties on product sales in addition to the licensing fee for use of the technology. SmithKline's topical offerings include the Oxy line of acne products in the U.S. and Rx Vectavir penciclovir 1% cream for cold sores, currently sold in the U.K. This is the second collaboration for the two companies; the firms signed an agreement in 1996 for a product that is not yet on shelves, SmithKline said...